AMSTERDAM—A molecularly-directed approach to treatment decision-making with patients who have metastatic cancers of unknown primary site was being urged at the 2013 European Cancer Congress by researc
AMSTERDAM—A molecularly-directed approach to treatment decision-making with patients who have metastatic cancers of unknown primary site was being urged at the 2013 European Cancer Congress by researchers from Arizona who have identified biomarkers predictive of drug response in more than 80 per cent of patients.
The traditional approach of basing therapy on guesswork about the site of origin needs to be abandoned according to Zoran Gatalica, MD, DSc, Executive Medical Director of Caris Life Sciences in Phoenix, Arizona, USA, and an Adjunct Professor of Pathology at Creighton University School of Medicine. He discusses his study in 1400 patients in whom 80 per cent were found to have actionable molecular targets. Sarah Maxwell reports.